Table 5 Patient characteristics stratified by statin user in patients with cardiovascular disorders.
Study characteristics | Measure | Total (N = 355) | Statin non-users (n = 290) | Statin users (n = 65) | P-value |
|---|---|---|---|---|---|
Age (years) | Median (IQR) | 76.7 (69.1–84.1) | 77.1 (69.1–84.4)) | 75.8 (67.7–83.5) | 0.395 |
Male Sex | No (%) | 260 (73.2%) | 207 (71.4%) | 53 (81.5%) | 0.094 |
BMI | Mean (SD) | 21.8 (0.22) | 21.5 (0.24) | 23.2 (0.48) | 0.002 |
Smoking | No. (%) | 130(41.3%) | 99(39.3%) | 31(49.2%) | 0.153 |
Alcoholism | No. (%) | 9 (2.5%) | 8 (2.8%) | 1 (1.5%) | 0.572 |
DM | No. (%) | 124(34.9%) | 91(31.4%) | 33(50.8%) | 0.003 |
HTN | No. (%) | 263(74.1%) | 207(71.4%) | 56(86.2%) | 0.014 |
Cancer | No. (%) | 73(20.6%) | 63(21.7%) | 10(15.4%) | 0.253 |
CKD Stage ≥ 3 | No. (%) | 141(39.7%) | 112(38.6%) | 29(44.6%) | 0.372 |
Asthma | No. (%) | 20(5.6%) | 19(6.6%) | 1(1.5%) | 0.113 |
COPD | No. (%) | 98(27.6%) | 79(27.2%) | 19(29.2%) | 0.746 |
Bronchiectasis | No. (%) | 17(4.8%) | 13(4.5%) | 4(6.2%) | 0.568 |
Pneumoconiosis | No. (%) | 5(1.4%) | 3(1.0%) | 2(3.1%) | 0.207 |
Liver cirrhosis | No. (%) | 6(1.7%) | 6(2.1%) | 0(0%) | 0.242 |
History of transplant | No. (%) | 7(1.9%) | 6(2.1%) | 1(1.5%) | 0.781 |
HIV | No. (%) | 4(1.1%) | 3(1.0%) | 1(1.5%) | 0.728 |
CAD | No. (%) | 291(81.9%) | 232(80%) | 59(90.8%) | 0.041 |
ATS | No. (%) | 102(28.7%) | 86(29.7%) | 16(24.6%) | 0.417 |
Baseline lipid levels | |||||
LDL | Mean (SD) | 86.1 (5.2) | 83.5 (24.8) | 89.6 (38.1) | 0.572 |
HDL | Mean (SD) | 37.3 (2.5) | 39.5 (19.6) | 34.3 (2.8) | 0.314 |
TCHOL | Mean (SD) | 150.3 (4.7) | 149.5 (6.2) | 151.5 (7.3) | 0.836 |
TG | Mean (SD) | 96.8 (6.8) | 86.3 (8.6) | 119.3 (9.8) | 0.024 |
TB disease characteristics | |||||
Initial AFB smear positivity | No. (%) | 144(42.1%) | 113(40.2%) | 31(50.8%) | 0.128 |
Initial AFB smear grade | Median (IQR) | 0 (0–2) | 0 (0–2) | 1 (0–2) | 0.111 |
Prior TB | No. (%) | 16(7.4%) | 11(6.1%) | 5(13.5%) | 0.117 |
Cavitary disease | No. (%) | 28(7.9%) | 22(7.6%) | 6(9.2%) | 0.657 |
Cardiovascular drug use | |||||
Metformin users | No. (%) | 55(15.5%) | 35(12.1%) | 20(30.8%) | < 0.001 |
Calcium channel blocker users | No. (%) | 107(30.1%) | 84(28.9%) | 23(35.4%) | 0.308 |
Outcome | |||||
All-cause mortality | No. (%) | 115 (34.5%) | 102 (37.9%) | 13 (20.3%) | 0.008 |
Infection-related mortality | No. (%) | 67 (20.1%) | 59 (21.9%) | 8 (12.5%) | 0.091 |
